Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ripertamab - Sinocelltech

Next Previous
X
Search
Drug Profile

Ripertamab - Sinocelltech

Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400

Latest Information Update: 30 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoprotein stimulants; Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Diffuse large B cell lymphoma
  • Phase III Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Jan 2025 Sinocelltech plans a clinical trial for Idiopathic thrombocytopenic purpura (Combination therapy, Treatment-experienced) in February 2025 (IV), (NCT06790888)
  • 29 Jan 2023 Registered for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in China (IV), prior to January 2023 (Sinocelltech pipeline, January 2023)
  • 11 Dec 2021 Safety and efficacy data from a phase III trial in Diffuse large B cell lymphoma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top